Chinmay Jani: Presenting collaborative project on HRR testing – OncoDaily
Chinmay Jani: Presenting collaborative project on HRR testing / cancer, Chinmay Jani, FLASCO, HRR testing guidelines, OncoDaily, Oncology, Pfizer Oncology,
Related Articles
Patty Kuderer leading Phil Fortunato in insurance commissioner race
The race for insurance commissioner has garnered more interest this year than in the past. Plus, a look at Tuesday results for other statewide races.
next level freedom election
Getting home b y dinner most nights WITHOUT bringing any work home Stabilizing staff turn-over in a mid-sized private practice without working 24/7 Six-figure raises…
10 Things We can See in Health Care in a Trump Administration
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 500+ Peer Reviewed papers,…
Cellular ATP demand creates metabolically distinct subpopulations of mitochondria
Nature – Mitochondria are able to maintain two competing metabolic pathways—oxidative phosphorylation and the reductive synthesis of proline and ornithine—by generating two…
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)
Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current stat
Paper: Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in…
Origins and impact of extrachromosomal DNA
Nature – A study examines the diversity of extrachromosomal DNA elements in cancer, and provides details on the frequency and origin of extrachromosomal DNA and…
Sample size for developing a prediction model with a binary…
When developing a clinical prediction model, the sample size of the development dataset is a key consideration. Small sample sizes lead to greater concerns of…
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929
To evaluate whether the addition of a poly (ADP-ribose) polymerase inhibitor (PARPi) talazoparib to maintenance immune checkpoint inhibitor (ICI) atezolizumab following frontline chemoimmunotherapy improved outcomes…
Early morning and evening activity could ‘reduce bowel cancer risk by 11%’
Research suggests time when physical activity taken is crucial, opening way to targeted prevention strategies